Question explored with the scientific record
Is aquablation good as seems heavily marketed
The short version: aquablation is a real procedure with decent short-term evidence, but the marketing is ahead of the data. You are trading a lower risk of sexual side effects for a higher risk of early complications, and the long-term durability is not yet proven.
The WATER trial [1] was a manufacturer-funded randomized double-blind study comparing aquablation to standard TURP in 116 men with 30–80 mL prostates. At 6 months, symptom scores improved by about 17 points with aquablation versus 15 with TURP, a statistically significant but clinically modest difference. The real selling point is sexual function: only 10% of aquablation patients reported anejaculation versus 36% with TURP [1]. The primary safety endpoint at 3 months also favored aquablation (26% versus 42%) [1].
But the safety advantage comes with a catch. The WATER II trial [2], a single-arm study of larger prostates (80–150 mL), found a 35% rate of Clavien-Dindo grade II or higher complications, compared to 20% in the smaller-prostate WATER trial. Larger prostates carry more risk, and the single-arm design means there is no direct comparison to TURP for that group. The evidence for large prostates is weaker.
| Outcome | Aquablation (30–80 mL) | TURP (30–80 mL) | Aquablation (80–150 mL) |
|---|---|---|---|
| Symptom improvement at 6 months | 16.9 points | 15.1 points | 17.1 points at 12 months |
| Anejaculation rate | 10% | 36% | Not reported |
| Serious complications (Clavien II+) | 20% | Not directly compared | 35% |
| Mean treatment time | 4 minutes | 27 minutes | 8 minutes |
The procedure is fast and preserves sexual function better than TURP. But the evidence base is thin: one randomized trial with 116 men, one single-arm study with 101 men, and no long-term data beyond 12 months [1, 2]. The 2025 review [3] notes that other minimally invasive options like water vapor therapy have 5-year data with retreatment rates around 4–5%. Aquablation does not have that track record yet.
My call: aquablation is a reasonable option for men who prioritize preserving ejaculatory function and have moderate-sized prostates, but the long-term durability is unproven and the complication rate in larger prostates is substantial. Confidence: moderate for short-term outcomes, low for long-term durability.
Sources used 3
-
WATER: A Double-Blind, Randomized, Controlled Trial of Aquablation ® vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia
This study compares the safety and efficacy of Aquablation versus transurethral resection of the prostate (TURP) for treating lower urinary tract symptoms due to benign prostatic hyperplasia, finding Aquablation to be noninferior with a lower risk of sexual dysfunction.
DOI: 10.1016/j.juro.2017.12.065 -
Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue trial (WATER) vs WATER II: comparing Aquablation therapy for benign prostatic hyperplasia in 30–80 and 80–150 mL prostates
Two international prospective trials (WATER and WATER II) compare Aquablation with standard surgical treatment across prostates of 30-80 mL and 80-150 mL, showing similar 12-month symptom relief and urinary function with shorter operative times and shorter hospital stays, while …
DOI: 10.1111/bju.14917 -
Management and Treatment of Benign Prostatic Hyperplasia Symptoms: Current Insights
A comprehensive, guideline-informed synthesis of BPH-related LUTS pathophysiology, diagnostic evaluation, and the full spectrum of current management options—from lifestyle and medical therapy to minimally invasive therapies and surgical interventions—emphasizing mechanism-based…
DOI: 10.2147/rru.s510367